News & Media

Read about our latest news and initiatives, and find more information about Acadia.

Featured Perspectives

February 21, 2023 Patient Story

Rett Stories: Lucy

February 16, 2023 Patient Story

What Eye-Gaze Artist Emily and Her Parents Want You To Know About Living With Rett

November 5, 2022 Employee Spotlight

Meet the Trailblazers: Parag Meswani

View All

Latest News Releases

March 10, 2023 General

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

February 27, 2023 Earnings

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview

February 14, 2023 General

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

View All

About Acadia

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders.

Learn More